Health officials are expanding recommendations for RSV vaccinations, particularly for older adults. CDC advises RSV shots for those aged 60-74 with health conditions and all individuals 75 and older. Moderna's RSV vaccine efficacy declines over time, causing market concerns.
GSK shares slide after US health agency narrows scope of RSV shots https://t.co/iy63F9Ezke https://t.co/iy63F9Ezke
🥜 Millions will be offered life-saving new jab to protect against 'severe' RSV free on the NHS - are you eligible? | The Sun https://t.co/QnVvo6XTQO
#Moderna RSV vaccine efficacy sinks over time, CDC documents show
Our take on day 1 of the ongoing ACIP meeting ... @PharmaPinkSheet #pinksheet #pharma: Revising Adult RSV Policy: US CDC Moves Toward Risk-Based Vaccine Recommendation https://t.co/MD1TO2BYUi
GSK Shares Slump After CDC Narrows Age Recommendation for RSV Shots https://t.co/g1si3efFuQ
The #CDC is now revising its recommendation for the #RSV vaccine - https://t.co/ke7UgvjYwH https://t.co/RC0D0dUKZB
$GSK (-1.6% pre) GSK shares slide after US health agency narrows scope of RSV shots - Reuters https://t.co/twYNmr4q7C
Revising Adult RSV Policy: US CDC Moves Toward Risk-Based Vaccine Recommendation https://t.co/2hp3hM0lWC #PinkSheet
GSK shares slide as US CDC limits RSV vaccine scope; analysts weigh in https://t.co/N9Wq42wtPy https://t.co/4fAby0A9zZ
GSK slides 6% after US CDC narrows scope of RSV shots https://t.co/YCR2wdBcda https://t.co/I0O8WGxreg
The U.S. CDC has narrowed its recommendation for respiratory syncytial virus (RSV) vaccines in older adults and held off on recommending them for adults under 60. Jefferies believes this raises risk for $GSK's Arexvy vaccine sales. JPMorgan analysts call the decision a…
GSK stock falls more at London open following RSV vaccination news https://t.co/DtdIlHpXlr
🔵 GSK SLIDES 6% AFTER US CDC NARROWS SCOPE OF RSV SHOTS GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus (RSV) vaccines and held off on recommending their use for those… https://t.co/uJ1SZb5ZST
GSK slumps after US health officials recommended restricting vaccination with its RSV shot to people who are older and more at risk https://t.co/IOmOOOQmsI
US health officials strengthen endorsement of RSV shots for oldest Americans https://t.co/Z49Ymm6UuG
Moderna RSV vaccine efficacy sinks over time, CDC documents show
Moderna RSV vaccine efficacy sinks over time, CDC documents show https://t.co/4v1UvOwc9O via @business
The new guidance recommends that everyone over the age of 75 get the #RSV vaccine, as well as anyone aged 60 to 74 who is at increased risk of severe RSV. https://t.co/w8nJjPiOlT
In an unusual move, federal health officials revised their recommendations for who should receive the vaccine against RSV. https://t.co/lUJsmsc9rD
CDC revises RSV vaccine recommendations https://t.co/ngaZVpynq9
(US) Advisory Committee on Immunization Practices (ACIP) unanimously voted in favor (11 Yes) to recommend that people ages 60 to 74 who have certain underlying conditions also receive a dose of the vaccine - ACIP Meeting (More at https://t.co/aDRM23LQx1)
(US) Advisory Committee on Immunization Practices (ACIP) unanimously voted in favor (11 Yes) to recommend that all people ages 75 and older receive a single lifetime dose - ACIP Meeting (More at https://t.co/KG1OlpbDYK)
U.S. health officials strengthen endorsement of RSV shots for oldest Americans https://t.co/Eu5xOSMZaH https://t.co/wxHo2z3jU8
Today, CDC updated its RSV vaccine recommendation for people 60 and older. If you have not received a dose, CDC recommends an RSV vaccine if you are: - Age 60–74 with certain chronic health conditions or live in a nursing home - Age 75 & older Read more: https://t.co/EzpTKtSrxE https://t.co/xMi3EmxOeA
The Centers for Disease Control and Prevention (CDC) updated its RSV vaccine guidance for seniors for this upcoming respiratory viral season, saying the new recommendations are meant to simplify decision-making for patients and clinicians. https://t.co/ikPKh8MXer
A CDC vaccine committee strongly recommended RSV shots for people 75 and older but said adults 60 to 74 should get vaccinated only if at higher risk for severe illness. https://t.co/YcQXZUpd2X
Makers of #RSV vaccines for older adults saw their plans to try to expand usage hit a significant hurdle on Wednesday. https://t.co/7jAWjwW0W6
“now recommends that all people ages 75 and older receive a single lifetime dose, and that people ages 60 to 74 who have certain underlying conditions also receive a dose of the vaccine.” https://t.co/v1wwKCisq4
CDC panel revises RSV vaccine recommendations for adults The new recommendations are easier to navigate in clinical settings and focus on older age groups who benefit most. https://t.co/tBqhXO2P8G https://t.co/BQp4Ooy9zb
“In the second vote, the committee recommended that people aged 60 to 74 who have health conditions that put them at high risk of severe illness from RSV should also get the vaccine.” https://t.co/OS9rXSeC1a
CDC advisors expand RSV vaccine recommendations, namely for adults 75 and older https://t.co/OOfPlD8Y9E
Pretty interesting discussion today at #ACIP on efforts by makers of #RSV vaccines for adults to expand usage. ACIP recommended everyone 75 & older get one, but deferred making a recommendation on use in people in their 50s, a blow to #GSK. https://t.co/Hcvd0vawPD
CDC advisors expanded their guidance for RSV vaccinations, though not to the degree that manufacturers had hoped. https://t.co/rUCPLI91Q1
Moderna shares sank after new data showed the efficacy of its RSV shot fell sharply in the second year and was lower than that of rival vaccines https://t.co/oJAayxmMDV
Moderna’s stock falls after data shows biotech’s RSV vaccine trails rivals after 18 months https://t.co/ELpeLOEoqW
Moderna Shares Fall on RSV Shot Jitters https://t.co/UqHgAw91vW
Moderna’s updated RSV vaccine disappoints with only 50% efficacy https://t.co/4hCCE6u0EK
Moderna says its RSV shot is 50% effective after 18 months $MRNA Flip a coin
US advisers to consider RSV shots as drugmaker GSK looks to keep market lead https://t.co/mRSqlTIsrE https://t.co/mRSqlTIsrE
$MRNA | Moderna reports its RSV shot mRESVIA showed 50% efficacy in preventing RSV after 18 months and 47.4% at 24 months. In comparison, GSK's Arexvy and Pfizer's RSV vaccines were both 78% effective over similar periods. Moderna cautions against direct comparisons due to…
Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday. https://t.co/qJHkhsAmNO https://t.co/qJHkhsAmNO
Market is hating Moderna's weak efficacy on RSV shot: https://t.co/V9LR1ZJxKg
Moderna says its RSV shot is 50% effective across a second season https://t.co/T6EGktFKUJ https://t.co/S9rQjppACp
$MRNA RSV Vaccine efficacy over 2 years <50% overall MRNA also decided to not show the RSV + Flu vaccine combo results https://t.co/MLDDFDOqfy
US advisers to consider RSV shots as GSK looks to keep market lead https://t.co/PJyOfenefe https://t.co/PJyOfenefe
Millions will be offered life-saving new jab to protect against ‘severe’ RSV free on the NHS https://t.co/sYvGKuHu96
Pregnant women and the elderly will be offered a vaccine on the NHS to protect against a respiratory virus that can cause serious complications https://t.co/aoL7yBgBrD
"The vaccine will be offered to those aged 18 or over who are at increased risk of contracting avian influenza due to their work or other circumstances” https://t.co/FpW3ALpkiv
UK Government Snubs GSK in Favor of Pfizer’s Rival RSV Shot https://t.co/rpOCzMvnNx
“The UK government has selected Pfizer to supply millions of respiratory syncytial virus (RSV) vaccine doses, snubbing local pharma company GSK and its competing product’ https://t.co/uAPXkLMAWE
Rallying in RSV vaccine race, Pfizer gains contract win over GSK in the UK https://t.co/BMsKN18EP5
RSV is a nasty respiratory illness - hospitalising thousands each winter. But we now have effective vaccines. And after a successful tender, I'm delighted we are launching a campaign this Autumn to protect pregnant mums, their infants and older adults. https://t.co/tq2fOxJ3Rc
Another win for GSK in RSV... as competitors Pfizer and Sanofi have struggled. https://t.co/sRBV5DLBi1
SCOOP: GSK has lost out to Pfizer on a contract to supply millions of doses of its blockbuster RSV vaccine to the UK in a setback for the local pharma giant. Pfizer will supply over 4.9 million doses to England and Northern Ireland starting in July. https://t.co/YCqdwI1otw
GSK has lost out to Pfizer on a contract to supply millions of doses of its blockbuster RSV vaccine to the UK in a setback for the local pharma giant https://t.co/CvENUaPEIA